Industry Symposium by Siemens Healthineers and Bayer
IND 3 - Interdisciplinary perspectives in Lung Cancer: advancements in screening modalities and surgical implications
IND 3-1
20 min
Lung Cancer Screening – why should we do it?
Isabelle Ayx, München / Germany
Learning Objectives
Morbidity and Mortality of Lung Cancer worldwide;
Chances and Risks of Lung Cancer Screening (LCS);
risk-based inclusion criteria of LCS.
Chances and Risks of Lung Cancer Screening (LCS);
risk-based inclusion criteria of LCS.
IND 3-2
20 min
What to know about your Lung-RADS score?
Nicola Sverzellati, Parma / Italy
Learning Objectives
1) To familiarize with the Lung-RADS 2022 categories
2) To focus on the new additions in Lung-RADS 2022
3) To familiarize with the management of benign and malignant nodules
2) To focus on the new additions in Lung-RADS 2022
3) To familiarize with the management of benign and malignant nodules
IND 3-3
20 min
New frontiers in thoracic surgery – Implications of lung cancer screening on surgical therapy
Isabelle Schmitt-Opitz, Züric / Switzerland
Learning Objectives
Implications of early detection of lung cancer on thoracic surgery
New approaches and modalities in thoracic surgery
Multidisciplinary set-up to defeat lung cancer
New approaches and modalities in thoracic surgery
Multidisciplinary set-up to defeat lung cancer
Lectures
1
Lung Cancer Screening – why should we do it?
20:00Isabelle Ayx, München / DE
2
What to know about your Lung-RADS score?
20:00Nicola Sverzellati, Parma / IT
3
New frontiers in thoracic surgery – Implications of lung cancer screening on surgical therapy
20:00Isabelle Schmitt-Opitz, Züric / CH